Adamis Pharmaceuticals Corporation
ADMP
NSC
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
0.41
USD
-0.03
(-7.73%)
Optionable: Yes Market Cap: 64 M 90-day average vol: 812,426
Previous close: 0.4478 Open: 0.4362 Bid: 0.4597 Ask: 0.4597
52 week range
0.31 1.48
Last updated: Monday 23rd May 2022
Valuation
Price per Sales TTM ($) | -33.68 |
Price per Book TTM ($) | 2.69 |
PE Ratio (TTM) | -1.50 |
Book Value per Share ($) | 0.23 |
5 Year PE Range-4.7 |
Returns
7 Day Return | -11.06% | |
1 Month Return | -7.15% | |
3 Month Return | -30.30% | |
1 Year Return | -44.45% | |
3 Year Return | -72.64% | |
5 Year Return | -89.80% | |
YTD Return | -31.70% |
Risk
Custom Beta One Year | 0.00 |
Custom Beta Three Years | 0.00 |
Beneish M Score | -1.55 |
Altman Z Score | -9.43 |
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 45.68 |
14 Day SMA ($) | 0.41 |
14 Day EMA ($) | 0.42 |
Money Flow Index | 72.36 |
Average True Range | 0.05 |
50 Day SMA ($) | 0.50 |
200 Day SMA ($) | 0.76 |
ADX | 20.86 |
MACD | -0.02 |
Growth
Free Cash Flow QoQ Growth | -30.40% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | -25.00% |
Revenue QoQ Growth | -252.56% |
EPS YoY Growth | 0.00% |
Profitability
Return on Assets TTM (%) | -132.52 |
Profit Margin TTM (%) | -1566.2 |
Return on Equity TTM (%) | -311.97 |
Return on Capital TTM (%) | -248.16 |
Interest Coverage Ratio | -5,202.70 |
Gross Margin TTM (%) | -211.1 |
Adamis Pharmaceuticals’ Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations
Yahoo Finance 2/28/2022
Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance 2/18/2022
Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19
Yahoo Finance 2/7/2022
Adamis Pharmaceuticals: Market Continues To Overlook TEMPOL's Potential To Be A Leading COVID-19 Therapeutic
Seeking Alpha 1/20/2022
Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19
Yahoo Finance 1/10/2022
Is the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock?
Yahoo Finance 12/20/2021
Adamis Pharmaceuticals: It's Now Or Never
Seeking Alpha 12/1/2021
Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™
Yahoo Finance 12/1/2021
Adamis Pharmaceuticals regains Nasdaq compliance
Seeking Alpha 11/23/2021
Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements
Yahoo Finance 11/23/2021
Adamis Pharmaceuticals Corporation (ADMP) CEO Dennis Carlo on Q3 2021 Result - Earnings Call Transcript
Seeking Alpha 11/23/2021
Adamis Pharmaceuticals EPS misses by $0.07, misses on revenue
Seeking Alpha 11/22/2021
Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update
Yahoo Finance 11/22/2021
Bitcoin mining operation on Navajo land in New Mexico 'positive for the community': Site manager
Yahoo Finance 11/22/2021
Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update
Yahoo Finance 11/19/2021
Adamis shares surge more than 42% after FDA approves opioid overdose treatment ZIMHI
Seeking Alpha 10/18/2021
Adamis Pharma Stock Jumps as FDA Clears Opioid-Overdose Treatment
Yahoo Finance 10/18/2021
Adamis Receives FDA Approval for ZIMHI
Yahoo Finance 10/18/2021
East Bay Parkinson's drug maker to be swallowed up in potential $450M deal
Yahoo Finance 10/11/2021
| NA |
|---|
| could not broadcast input array from shape (20) into shape (0) |
|---|
ADMP Income Statement
Annual
| Mar-13 | Mar-14 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 6 M | 13 M | 15 M | 22 M | 3 M |
| Cost of sales | -36792 | -343456 | -888367 | -990290 | 2 M | 4 M | 7 M | 13 M | 4 M |
| Gross operating profit | 0 | 0 | 0 | 0 | 2 M | 6 M | 5 M | 7 M | -4 M |
| Selling Gen & administrative expense | 2 M | 3 M | 5 M | 9 M | 17 M | 23 M | 26 M | 25 M | 20 M |
| Research & development expense | 1 M | 1 M | 4 M | 5 M | 10 M | 8 M | 19 M | 10 M | 8 M |
| Operating income | -3 M | -4 M | -8 M | -14 M | -25 M | -25 M | -39 M | -29 M | -32 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | -2 M | 5 M | -988303 | 278431 | 1 M | -1 M | -10517 | 2 M | -4 M |
| Pre-tax Income (EBT) | -7 M | -8 M | -9 M | -14 M | -24 M | -26 M | -39 M | -28 M | -36 M |
| Income taxes | 0 | 0 | 0 | 0 | -5 M | -339391 | -369340 | 8672 | 2400 |
| Net income from total operations | -7 M | -8 M | -9 M | -14 M | -19 M | -26 M | -39 M | -28 M | -49 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -7 M | -8 M | -9 M | -14 M | -19 M | -26 M | -39 M | -28 M | -49 M |
| Preferred dividends | N/A | N/A | N/A | N/A | 1 M | N/A | N/A | N/A | N/A |
| Net income available for common | -7 M | -8 M | -9 M | -14 M | -21 M | -26 M | -39 M | -28 M | -36 M |
| Depreciation | 36792 | 343456 | 888367 | 990290 | 3 M | 3 M | 3 M | 3 M | 2 M |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -5 M | 766405 | -8 M | -13 M | -21 M | -23 M | -36 M | -24 M | -34 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -1.23 | -1.11 | -0.89 | -1.02 | -1.19 | -0.9 | -1 | -0.55 | -0.64 |
| Diluted EPS total | -1.23 | -1.22 | -0.89 | -1.03 | -1.19 | -0.9 | -1 | -0.55 | -0.64 |
Top MarketXLS Rank stocks
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!